"Our expectation for 2008 net cash burn remains in line with prior guidance of $135-155 million, and our cash position remains strong," said Tim Barabe, Senior Vice President and Chief Financial Officer, HGS. "This includes $100-120 million in ABthrax revenue that we expect to receive in late 2008."
HIGHLIGHTS OF RECENT PROGRESS
Albuferon(R): Treatment Phase of Both Phase 3 Trials Completed; Timeline on Track for Phase 3 Data and Filing of Marketing Applications
In July 2008, HGS completed the treatment phase of ACHIEVE 1, one of two Phase 3 trials of Albuferon (albinterferon alfa-2b) in combination with ribavirin in treatment-nave patients with chronic hepatitis C. The Company completed the treatment phase of ACHIEVE 2/3 in April 2008. ACHIEVE 1 is being conducted in patients with genotype 1 chronic hepatitis C; ACHIEVE 2/3 is being conducted in patients with genotypes 2 and 3 chronic hepatitis C. HGS remains on track to have ACHIEVE 2/3 data in December 2008 and ACHIEVE 1 data by spring 2009, with filing of global marketing applications by fall 2009. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
LymphoStat-B(R): Enrollment of Patients into Screening Completed in Second Phase 3 Trial in Systemic Lupus Erythematosus; Timeline on Track for Phase 3 Data and Filing of Biologics License Application
HGS has completed the enrollment of patients into screening in
BLISS-76, the second of two Phase 3 trials of LymphoStat-B (belimumab) in
active systemic lupus erythematosus (SLE), and expects to complete
randomization and initial dosing in the study in August 2008. The Company
completed randomization and initial dosing in BLISS-52 in April 2008. The
first Phase 3 data are expected by mid-2009, and all Phase 3 data to
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved